Evolva (Pharmaceutical company)

Evolva (Pharmaceutical company)

Biotech company that develops and commercializes ingredients for use in food, nutrition, personal healthcare, agriculture, and other sectors.

Evolva is a publicly traded, biotech company based in Reinach, Switzerland. It focuses on discovering, producing, and supplying sustainable ingredients, in particular, for health, wellness, and nutrition.

Using synthetic biology, Evolva takes baker's yeast and gives it the ability to make the same ingredient that would normally be made by a plant or animal. The company's lead products are stevia sweeteners, nootkatone, and resveratol. It has five key products, which are:

  • NootkaShield
  • Veri-te
  • EveNootkatone
  • EveValencene
  • EverSweet Stevia

NootkaShield is a product that combines Evolva's yeast fermentation process with a properietary conversion technique to product. It's main ingredient is Nootkatone, which is known to effectively repel and control a range of insect pests, including ticks, mosquitos, and other nuisance insects. NootkaShield is aimed to be used for pest control at a commercial scale and is available for research, product development, testing, and potential registration.

Resveratol is a polyphenol that is found in several types of plants and has shown evidence of working at a cellular level to assist healthy aging. Evolva produces resveratol under the name Veri-te, which can be formulated into multiple applications, including capsules, tablets, softgels, liquid shots, beverages, powder sticks, film strips, chocolate, chewing gum, creams, serum, and cosmetics.

Evolva also has some products approved flavor and fragrance applications. Normally extracted from the skin of grapefruits, Evolva's nootkatone (EveNootkatone) flavor and fragrance is instead brewed from sugar. Another flavor and fragrance the company produces is EveValencene, a citrus aroma (valencene) that is characteristic in the smell of oranges. This too is brewed from sugar.

EverSweet is a calorie-free sweetener that is made using Evolva's yeast fermentation process. It was launched in 2018 in partnership with Cargill. The latter is also the company that manufactures EverSweet.

Timeline

December 7, 2009
Evolva raises a $27,500,000 series B round from Aravis Ventures, Auriga Partners and Wellington Partners.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Evolva (Pharmaceutical company) Series B round
27,500,000
December 7, 2009
2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Anupam Paliwal

Employee

Branislav Stambolija

Employee

Giovanni Salerno

Senior VP, NootkaShield

Jean-Philippe Meyer

VP, Regulatory Affairs

Marc Duckeck

Investor

Melya Hughes Crameri

Investor

Michael Malone

VP, Sales and Marketing

Oliver Walker

CEO

peter bikundo

Employee

Peter Dudek

Investor

Philippe Prochasson, Ph.D.

Employee

Scott Fabro

COO

Further reading

Title
Author
Link
Type
Date

Evolva to axe almost half its workforce in restructuring overhaul

foodnavigator.com

Web

EVOLVA: an Interview with CEO Neil Goldsmith | PLOS Synthetic Biology Community

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.